Pre-made Tesnatilimab benchmark antibody ( Whole mAb, anti-KLRK1 therapeutic antibody, Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tesnatilimab biosimilar, Whole mAb, Anti-KLRK1 Antibody: Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tesnatilimab (formerly JNJ 4500) is being developed by Janssen Biotech, for the treatment of autoimmune diseases, including Crohn's disease.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-566-1mg	1mg	3090
GMP-Bios-ab-566-10mg	10mg	Inquiry
GMP-Bios-ab-566-100mg	100mg	Inquiry
GMP-Bios-ab-566-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tesnatilimab biosimilar, Whole mAb, Anti-KLRK1 Antibody: Anti-CD314/D12S2489E/KLR/NKG2-D/NKG2D therapeutic antibody
INN Name	Tesnatilimab
Target	KLRK1
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Janssen Research & Development
Conditions Approved	na
Conditions Active	Crohn's disease
Conditions Discontinued	na
Development Tech	na